5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression >/= 50% Advanced NSCLC. Velcheti V, Rai P, Kao YH, Chirovsky D, et al. Clin Lung Cancer 2024;25:502-508.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Velcheti V, Rai P, Kao YH, Chirovsky D, et al. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression >/= 50% Advanced NSCLC. Clin Lung Cancer 2024;25:502-508.
PMID: 38880664